Review maps multi-target herbal pathways against avian IBV
Bottom line
Version 1
A new narrative review in Frontiers in Veterinary Science argues that herbal medicines and traditional Chinese medicine-derived compounds may have a broader role against avian infectious bronchitis virus, or IBV, than single-pathway antivirals. The paper, by Chenyuan Zhang, synthesizes published evidence suggesting these products may act across multiple stages of infection, including viral entry, replication, immune signaling, inflammation, and oxidative stress. The review frames herbal therapies as host-directed, multi-target adjuncts rather than replacements for core IBV control measures such as vaccination and biosecurity. (frontiersin.org)
Why it matters: For veterinary professionals working in poultry health, the review is less about a practice-changing treatment today and more about where the research pipeline is heading. IBV remains difficult to control because vaccines can be strain-specific and viral variation can limit cross-protection, which is one reason researchers keep exploring complementary approaches. Prior studies highlighted in the broader literature have linked herbal formulations or plant compounds to interferon and JAK/STAT signaling, reduced inflammatory cytokines, and improved protection in experimental chicken embryo or chicken models, but the evidence base is still largely preclinical and heterogeneous. (link.springer.com)
What to watch: The next step is whether these mechanistic findings translate into standardized, field-tested products with reproducible efficacy, dosing, safety, and regulatory pathways in commercial poultry settings. (frontiersin.org)
Key facts
- Article type
- Narrative review
- Journal
- Frontiers in Veterinary Science
- Topic
- Herbal medicines and traditional Chinese medicine compounds against avian infectious bronchitis virus (IBV)
- Main claim
- These products may act across viral entry, replication, immune signaling, inflammation, and oxidative stress
- Role in care
- Host-directed, multi-target adjuncts, not replacements for vaccination and biosecurity
- IBV challenge
- Vaccine-based control is complicated by viral diversity and ongoing evolution
- Evidence base
- Still largely preclinical and heterogeneous
- Next step
- Standardized, field-tested products with reproducible efficacy, dosing, safety, and regulatory pathways
Version 2
A new review in Frontiers in Veterinary Science pulls together the growing, but still early-stage, literature on herbal medicines against avian infectious bronchitis virus and argues that the most important theme is convergence: many compounds appear to work through shared host-directed and multi-stage antiviral pathways. Author Chenyuan Zhang describes a framework in which herbal medicines and traditional Chinese medicine compounds may help modulate immune responses, limit inflammation, manage oxidative stress, and interfere with different phases of IBV infection. (frontiersin.org)
That framing matters because IBV remains a persistent challenge in poultry medicine. Infectious bronchitis is a highly contagious avian coronavirus disease with respiratory, renal, reproductive, and performance consequences, and vaccine-based control is complicated by the virus’s diversity and ongoing evolution. Earlier reviews have already pointed to medicinal plant derivatives as a possible supplementary strategy, especially where conventional prevention does not fully cover emerging or heterologous strains. (link.springer.com)
The new article is a narrative review rather than a new efficacy trial, so its contribution is synthesis, not definitive proof of a product benefit. According to the Frontiers abstract, the review searched major English- and Chinese-language databases for studies on IBV, herbal medicines, natural compounds, antiviral activity, and host-directed mechanisms. Its central claim is that despite variation among products and study designs, the literature points toward recurring pathways tied to innate immune regulation and multi-target antiviral activity. (frontiersin.org)
That conclusion lines up with several recent and prior studies in the space. A 2024 One Health Advances paper on Ban-Qin-Fei-Re-Qing oral liquid reported protection in chicken embryo and chicken models and linked its activity to type I interferon and JAK/STAT signaling. A 2021 Frontiers study found that Shegandilong granule combined with doxycycline improved immune responses, reduced inflammatory cytokines, and inhibited IBV replication in broilers. More recently, a 2026 Poultry Science report indexed in PubMed found cannabidiol inhibited IBV in vitro and in vivo, with transcriptomic findings again pointing to immune-related signaling, including JAK-STAT and interferon-stimulated gene expression. (link.springer.com)
There does appear to be a broader industry and research push to understand phytogenic or herbal antivirals in poultry, but expert commentary tied specifically to this new review was limited in publicly accessible sources. What is available suggests a consistent scientific rationale: researchers are looking for adjunctive tools that may reduce viral replication, support host defenses, and potentially lessen dependence on narrower interventions. At the same time, the literature repeatedly acknowledges that many findings come from embryo studies, cell systems, or controlled challenge models, which limits direct translation to commercial flock medicine. (frontiersin.org)
Why it matters: For veterinary professionals, this is best read as a map of emerging mechanisms, not a signal to change protocols. The review helps organize a fragmented evidence base around a practical idea: if multiple herbal compounds converge on interferon signaling, inflammatory control, and oxidative stress pathways, they may eventually be developed as adjuncts to vaccination, supportive care, and flock-level prevention. But the gap between mechanistic promise and deployable veterinary products remains wide, especially around formulation standardization, active ingredient consistency, dose selection, residue considerations, safety, and regulatory acceptance. (frontiersin.org)
That distinction is important in poultry practice, where reproducibility and flock-level economics matter as much as biologic plausibility. Herbal mixtures can vary substantially by source material and manufacturing method, and many published studies evaluate products that are difficult to compare head-to-head. For veterinarians advising integrators, producers, or pet parents with backyard flocks, the current evidence supports cautious interest, not routine recommendation as a substitute for proven prevention programs. (link.springer.com)
What to watch: The field now needs standardized formulations, larger in vivo studies, commercial-setting trials, and clearer regulatory pathways before host-directed herbal antivirals move from interesting review topic to practical IBV management tool. (frontiersin.org)